

# Piet Ost

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3450447/publications.pdf>

Version: 2024-02-01

206  
papers

9,631  
citations

53794

45  
h-index

45317

90  
g-index

213  
all docs

213  
docs citations

213  
times ranked

10447  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU International, 2022, 129, 699-707.	2.5	19
2	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. European Journal of Cancer, 2022, 160, 24-60.	2.8	12
3	Stereotactic Ablative Radiotherapy as a Tool in Renal Cell Carcinoma for Building RAPPORT with Systemic Therapy. European Urology, 2022, 81, 373-374.	1.9	0
4	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 80-91.	0.8	5
5	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer and Prostatic Diseases, 2022, 25, 713-719.	3.9	17
6	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	3.9	14
7	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
8	Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer. European Urology Focus, 2022, 8, 1617-1621.	3.1	7
9	Impact of radiotherapy parameters on the risk of lymphopenia in urological tumors: A systematic review of the literature. Radiotherapy and Oncology, 2022, 170, 64-69.	0.6	4
10	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	1.9	51
11	Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. JCO Precision Oncology, 2022, 6, e2100543.	3.0	7
12	Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. Radiotherapy and Oncology, 2022, 172, 1-9.	0.6	4
13	Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate, 2022, 82, .	2.3	3
14	Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials.. Journal of Clinical Oncology, 2022, 40, 5025-5025.	1.6	3
15	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. European Urology Focus, 2021, 7, 742-751.	3.1	19
16	Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries. World Journal of Urology, 2021, 39, 317-326.	2.2	18
17	When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities. European Urology, 2021, 79, 565-567.	1.9	25
18	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology Oncology, 2021, 4, 301-304.	5.4	2

#	ARTICLE	IF	CITATIONS
19	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	21.4	264
20	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021, 80, 632-640.	1.9	61
21	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. <i>BMC Urology</i> , 2021, 21, 18.	1.4	3
22	Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 194-194.	1.6	10
23	The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases. <i>European Urology Focus</i> , 2021, 7, 241-244.	3.1	20
24	Spatiotemporal Evolution of Radiation Myositis on 18F-FDG PET/CT Following Hypofractionated Radiotherapy of Intramuscular Melanoma Metastases. <i>Clinical Nuclear Medicine</i> , 2021, 46, e384-e386.	1.3	3
25	Adoption of single fraction radiotherapy for uncomplicated bone metastases in a tertiary centre. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 64-69.	1.7	6
26	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 714-730.	5.4	16
27	Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 1588.	3.7	1
28	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.6	11
29	The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry. <i>European Urology Open Science</i> , 2021, 29, 68-76.	0.4	23
30	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. <i>Cancer Treatment Reviews</i> , 2021, 98, 102206.	7.7	30
31	Extreme Hypofractionation with SBRT in Localized Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 2933-2949.	2.2	6
32	Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. <i>European Urology</i> , 2021, 80, 306-315.	1.9	64
33	Stereotactic Radiotherapy for Oligoproggressive Disease: A New Frontier in Kidney Cancer. <i>European Urology</i> , 2021, 80, 701-702.	1.9	1
34	Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVIS. <i>European Urology</i> , 2021, 80, 415-416.	1.9	0
35	The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium. <i>European Urology</i> , 2021, 80, 450-453.	1.9	11
36	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. <i>Nature Communications</i> , 2021, 12, 184.	12.8	85

#	ARTICLE	IF	CITATIONS
37	Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial. <i>BMC Cancer</i> , 2021, 21, 1113.	2.6	10
38	Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. <i>European Urology</i> , 2021, 81, 216-216.	1.9	1
39	Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 914-923.	5.4	23
40	Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. <i>European Urology Oncology</i> , 2020, 3, 455-463.	5.4	17
41	Reply to Pirus Ghadjar, Thomas Wiegela's Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy. <i>Elective Nodal Radiotherapy</i> . <i>Eur Urol</i> 2019;76:732-9. <i>European Urology</i> , 2020, 77, e62-e63.	1.9	2
42	Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy: Systematic review of the recent literature. <i>International Journal of Urology</i> , 2020, 27, 98-107.	1.0	21
43	Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. <i>Lancet Oncology</i> , The, 2020, 21, e18-e28.	10.7	588
44	Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020, 3, 183-197.	5.4	46
45	PSMA PET-CT redefines nonmetastatic castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 133-134.	3.8	5
46	Comparative analysis of somatic variant calling on matched FF and FFPE WGS samples. <i>BMC Medical Genomics</i> , 2020, 13, 94.	1.5	12
47	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 541281.	2.8	15
48	How to deal with steroids use in the management of metastatic prostate cancer during pandemic. <i>Translational Andrology and Urology</i> , 2020, 9, 1546-1549.	1.4	0
49	Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. <i>European Urology Oncology</i> , 2020, 3, 565-581.	5.4	46
50	Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review. <i>Acta Oncologica</i> , 2020, 59, 1224-1234.	1.8	27
51	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.8	11
52	The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. <i>Trials</i> , 2020, 21, 579.	1.6	16
53	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278
54	A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. <i>Cancers</i> , 2020, 12, 132.	3.7	7

#	ARTICLE	IF	CITATIONS
55	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2020, 78, 138-142.	1.9	55
56	Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. <i>Journal of Urology</i> , 2020, 203, 338-343.	0.4	53
57	Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer. <i>EJNMMI Research</i> , 2020, 10, 14.	2.5	13
58	Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10-10.	1.6	82
59	Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy. <i>Future Oncology</i> , 2020, 16, 1083-1189.	2.4	0
60	Imaging modalities in synchronous oligometastatic prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2573-2583.	2.2	16
61	Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. <i>World Journal of Urology</i> , 2019, 37, 243-251.	2.2	37
62	Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2565-2571.	2.2	10
63	Pelvic lymph node dissection in prostate cancer staging: evaluation of morbidity and oncological outcomes. <i>Acta Chirurgica Belgica</i> , 2019, 119, 103-109.	0.4	7
64	Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. <i>World Journal of Urology</i> , 2019, 37, 2607-2613.	2.2	18
65	Re: GaÃ«tan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? <i>Eur Urol</i> 2019;76:265â€“7. <i>European Urology</i> , 2019, 76, e147-e148.	1.9	3
66	Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. <i>European Urology</i> , 2019, 76, 732-739.	1.9	99
67	Has the PROPHECY of AR-V7 Been Fulfilled?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2181-2182.	1.6	7
68	Developments in oligometastatic hormone-sensitive prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2545-2547.	2.2	2
69	Hereditary prostate cancer â€“ Primetime for genetic testing?. <i>Cancer Treatment Reviews</i> , 2019, 81, 101927.	7.7	20
70	A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET). <i>BMC Cancer</i> , 2019, 19, 876.	2.6	10
71	Readdressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. <i>BJU International</i> , 2019, 124, 35-39.	2.5	4
72	What Is Oligometastatic Prostate Cancer?. <i>European Urology Focus</i> , 2019, 5, 159-161.	3.1	24

#	ARTICLE	IF	CITATIONS
73	Oligometastatic prostate cancer: The game is afoot. <i>Cancer Treatment Reviews</i> , 2019, 73, 84-90.	7.7	41
74	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2019, 75, 707-711.	1.9	89
75	Re: Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. <i>European Urology</i> , 2019, 76, 538-539.	1.9	1
76	REQUIRE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 138, 59-67.	0.6	53
77	Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18â€ƒ) choline PETâ€ƒCT. <i>European Journal of Cancer Care</i> , 2019, 28, e13093.	1.5	15
78	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 828-835.	0.8	46
79	Radiation Dosimetry and Biodistribution of <sup>18</sup> F-PSMA-11 for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1736-1742.	5.0	34
80	Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. <i>Current Oncology Reports</i> , 2019, 21, 43.	4.0	9
81	Aggressive variants of prostate cancer â€œ Are we ready to apply specific treatment right now?. <i>Cancer Treatment Reviews</i> , 2019, 75, 20-26.	7.7	23
82	Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 1543-1549.	2.2	19
83	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. <i>World Journal of Urology</i> , 2019, 37, 2631-2637.	2.2	69
84	Adding Colour to the Grey Zone of Advanced Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 123-124.	3.1	5
85	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	1.9	14
86	Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than Answers. <i>European Urology</i> , 2019, 75, 61-62.	1.9	0
87	<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1766-1773.	7.0	117
88	Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. <i>World Journal of Urology</i> , 2019, 37, 2557-2564.	2.2	23
89	Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 393-401.	2.0	39
90	Re: [177Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study. <i>European Urology</i> , 2019, 75, 536-537.	1.9	2

#	ARTICLE	IF	CITATIONS
91	Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 76, 493-504.	1.9	111
92	Understanding physical activity behavior in patients with bladder cancer before and after radical cystectomy: a qualitative interview study. <i>Clinical Rehabilitation</i> , 2019, 33, 750-761.	2.2	14
93	Abiraterone and spironolactone in prostate cancer: a combination to avoid. <i>Acta Clinica Belgica</i> , 2019, 74, 439-444.	1.2	14
94	Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. <i>European Urology</i> , 2019, 75, 826-833.	1.9	48
95	Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. <i>European Urology Focus</i> , 2019, 5, 171-178.	3.1	50
96	Circulating tumor DNA in patients with metastatic urothelial cancer: concordance of genomic findings with matched tissue biopsies.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16036-e16036.	1.6	1
97	Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 457-457.	1.6	3
98	Is 68 Ga-Prostate-specific Membrane Antigenâ€“ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?. <i>European Urology</i> , 2018, 73, 662-663.	1.9	1
99	Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology. <i>World Journal of Urology</i> , 2018, 36, 1489-1494.	2.2	1
100	Metastatic burden in newly diagnosed hormone-naïve metastatic prostate cancer: Comparing definitions of CHARTED and LATITUDE trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 158.e13-158.e20.	1.6	27
101	Circulating tumor cells and survival in abirateroneâ€“and enzalutamideâ€“treated patients with castrationâ€“resistant prostate cancer. <i>Prostate</i> , 2018, 78, 435-445.	2.3	21
102	4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 866-870.	0.8	7
103	Pembrolizumab for the treatment of bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 107-114.	2.4	12
104	Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 197-205.e5.	1.9	7
105	Effects of radiation on the metastatic process. <i>Molecular Medicine</i> , 2018, 24, 16.	4.4	42
106	Live to SABR Another Day?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1097.	0.8	0
107	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. <i>European Urology</i> , 2018, 74, 134-137.	1.9	13
108	Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. <i>European Urology</i> , 2018, 73, 40-50.	1.9	107

#	ARTICLE	IF	CITATIONS
109	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488
110	A systematic review of exercise and psychosocial rehabilitation interventions to improve health-related outcomes in patients with bladder cancer undergoing radical cystectomy. <i>Clinical Rehabilitation</i> , 2018, 32, 594-606.	2.2	29
111	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. <i>European Urology</i> , 2018, 73, 512-518.	1.9	36
112	Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects in men with prostate cancer. <i>BJU International</i> , 2018, 121, 610-618.	2.5	10
113	AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?. <i>World Journal of Urology</i> , 2018, 36, 149-151.	2.2	1
114	Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. <i>Practical Radiation Oncology</i> , 2018, 8, 28-39.	2.1	140
115	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 436-444.	1.9	60
116	Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2351-2352.	1.6	4
117	Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?. <i>Oncotarget</i> , 2018, 9, 34196-34197.	1.8	7
118	Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 446-453.	1.6	972
119	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	10.7	90
120	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. <i>Genome Medicine</i> , 2018, 10, 85.	8.2	94
121	Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 488-497.	1.6	0
122	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. <i>Lancet Oncology</i> , The, 2018, 19, e534-e545.	10.7	98
123	How can we expand active surveillance criteria in patients with low and intermediate risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. <i>BJU International</i> , 2018, 122, 823-830.	2.5	27
124	Stereotactic Body Radiotherapy for Primary Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878963.	1.9	16
125	It Ain't™t Over Till the Fat Lady Sings: The POPSTAR Trial. <i>European Urology</i> , 2018, 74, 463-464.	1.9	5
126	Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1159-e1169.	1.9	6



#	ARTICLE	IF	CITATIONS
127	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	21.4	652
128	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	12.8	88
129	Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. <i>Oncotarget</i> , 2018, 9, 25216-25224.	1.8	26
130	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11256.	1.0	12
131	The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 152.e13-152.e22.	1.6	2
132	Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. <i>European Urology</i> , 2017, 72, 689-709.	1.9	73
133	A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. <i>Journal of Translational Medicine</i> , 2017, 15, 21.	4.4	21
134	Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e623-e632.	1.9	71
135	Whole pelvis radiotherapy for pathological node-positive prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 444-451.	2.0	13
136	Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol. <i>BMJ Open</i> , 2017, 7, e016054.	1.9	7
137	Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the <sc>SACC</sc> 09/10 randomized trial on prostate cancer. <i>BJU International</i> , 2017, 120, E45-E51.	2.5	13
138	Editorial Comment. <i>Urology</i> , 2017, 109, 151-152.	1.0	1
139	What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?. <i>Future Oncology</i> , 2017, 13, 2121-2124.	2.4	2
140	Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. <i>Eur Urol</i> 2017;72:1-3. <i>European Urology</i> , 2017, 72, e66-e67.	1.9	2
141	Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 587-595.	1.8	37
142	Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy. <i>European Urology Focus</i> , 2017, 3, 538-544.	3.1	39
143	Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. <i>BJU International</i> , 2017, 120, 815-821.	2.5	53
144	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. <i>Journal of Translational Medicine</i> , 2017, 15, 150.	4.4	26

#	ARTICLE	IF	CITATIONS
145	Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial. <i>BMC Cancer</i> , 2017, 17, 308.	2.6	7
146	Variations in target volume definition and dose to normal tissue using anatomic versus biological imaging ( <sup>18</sup> F- <sup>18</sup> F-FDG-PET) in the treatment of bone metastases: results from a 3-arm randomized phase II trial. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 124-132.	1.8	3
147	Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients. <i>Diagnostics</i> , 2017, 7, 56.	2.6	8
148	Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. <i>Radiation Oncology</i> , 2017, 12, 157.	2.7	28
149	Estimating the incidence of oligorecurrent and potentially salvageable prostate cancer on 18F-Choline PET-CT: Screening phase of the STOMP randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 153-153.	1.6	4
150	Circulating tumour cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5049-5049.	1.6	0
151	Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and 2 in a Cohort of 245 Patients with Histopathological Reference and Long-Term Follow-Up. <i>Journal of the Belgian Society of Radiology</i> , 2016, 100, 108.	0.2	5
152	Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicity. <i>Radiotherapy and Oncology</i> , 2016, 119, 398-404.	0.6	24
153	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2016;70:21-30. <i>European Urology</i> , 2016, 70, e11-e12.	1.9	5
154	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 121, 431-439.	0.6	98
155	The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 323-332.	0.8	19
156	Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey. <i>European Urology Focus</i> , 2016, 2, 514-521.	3.1	11
157	Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. <i>Insights Into Imaging</i> , 2016, 7, 205-214.	3.4	45
158	Reply from Authors re: Vincent Khoo. Is There Another Bite of the Cherry? The Case for Radical Local Therapy for Oligometastatic Disease in Prostate Cancer. <i>Eur Urol</i> 2016;69:13-14. <i>European Urology</i> , 2016, 69, 14-15.	1.9	0
159	Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naïve Recurrence: A Multi-institutional Analysis. <i>European Urology</i> , 2016, 69, 9-12.	1.9	250
160	Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	26
161	The Role of Androgen Receptor Expression in the Curative Treatment of Prostate Cancer with Radiotherapy: A Pilot Study. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	7
162	The oncologic role of local treatment in primary metastatic prostate cancer. <i>World Journal of Urology</i> , 2015, 33, 755-761.	2.2	14

#	ARTICLE	IF	CITATIONS
163	Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. <i>Journal of Urology</i> , 2015, 194, 983-988.	0.4	83
164	Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience. <i>Acta Oncol</i> , 2015, 54, 854-861.	1.8	9
165	What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 164.e1-164.e9.	1.6	35
166	Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 71.e1-71.e9.	1.6	62
167	Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: A 3-arm randomized phase II trial. <i>Radiotherapy and Oncology</i> , 2015, 115, 272-278.	0.6	22
168	Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. <i>Journal of Clinical Oncology</i> , 2015, 33, 4158-4166.	1.6	99
169	Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. <i>European Urology Focus</i> , 2015, 1, 173-184.	3.1	11
170	The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. <i>Oncolmmunology</i> , 2015, 4, e1042198.	4.6	36
171	Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature. <i>European Urology</i> , 2015, 67, 852-863.	1.9	303
172	Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e1-265.e7.	1.6	14
173	Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. <i>BJU International</i> , 2015, 115, 571-579.	2.5	29
174	Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5038-5038.	1.6	2
175	Systematic ultrasound-guided saturation and template biopsy of the prostate: indications and advantages of extended sampling. <i>Archivos Espanoles De Urologia</i> , 2015, 68, 296-306.	0.2	5
176	Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. <i>BMC Cancer</i> , 2014, 14, 671.	2.6	106
177	Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. <i>Prostate</i> , 2014, 74, 297-305.	2.3	120
178	Rectal toxicity after intensity modulated radiotherapy for prostate cancer: Which rectal dose volume constraints should we use?. <i>Radiotherapy and Oncology</i> , 2014, 113, 398-403.	0.6	28
179	Re: Stephen H. Culp, Paul F. Schellhammer, Michael B. Williams. Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study. <i>Eur Urol</i> 2014;65:1058-66. <i>European Urology</i> , 2014, 65, e97-e98.	1.9	1
180	Integrated models for the prediction of late genitourinary complaints after high-dose intensity modulated radiotherapy for prostate cancer: Making informed decisions. <i>Radiotherapy and Oncology</i> , 2014, 112, 95-99.	0.6	33

#	ARTICLE	IF	CITATIONS
181	Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. <i>Radiation Oncology</i> , 2014, 9, 135.	2.7	220
182	Hair-sparing whole brain radiotherapy with volumetric arc therapy in patients treated for brain metastases: dosimetric and clinical results of a phase II trial. <i>Radiation Oncology</i> , 2014, 9, 170.	2.7	21
183	Radiotherapy for renal-cell carcinoma. <i>Lancet Oncology, The</i> , 2014, 15, e170-e177.	10.7	226
184	Intensity modulated radiotherapy induces pro-inflammatory and pro-survival responses in prostate cancer patients. <i>International Journal of Oncology</i> , 2014, 44, 1073-1083.	3.3	19
185	Use of EORTC Target Definition Guidelines for Dose-Intensified Salvage Radiation Therapy for Recurrent Prostate Cancer: Results of the Quality Assurance Program of the Randomized Trial SAKK 09/10. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 534-541.	0.8	23
186	Early biomarkers related to secondary primary cancer risk in radiotherapy treated prostate cancer patients: IMRT versus IMAT. <i>Radiotherapy and Oncology</i> , 2013, 107, 377-381.	0.6	11
187	Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 27-32.	1.9	169
188	Acute Radiation-Induced Nocturia in Prostate Cancer Patients Is Associated With Pretreatment Symptoms, Radical Prostatectomy, and Genetic Markers in the TGF $\beta$ 21 Gene. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 393-399.	0.8	27
189	Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: Early late toxicity and 3-year clinical outcome. <i>Radiotherapy and Oncology</i> , 2013, 109, 229-234.	0.6	27
190	Developments in External Beam Radiotherapy for Prostate Cancer. <i>Urology</i> , 2013, 82, 5-10.	1.0	16
191	Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: Toxicity and matched case comparison with postoperative prostate bed-only radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 109, 222-228.	0.6	17
192	Management of High-Risk/Locally Advanced Disease. , 2013, , 831-842.		0
193	Management of Locally Recurrent Disease. , 2013, , 817-829.		0
194	External Beam Radiotherapy for Low-Risk Prostate Cancer. , 2013, , 709-717.		0
195	Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-8.	1.3	5
196	High-Dose Adjuvant Radiotherapy After Radical Prostatectomy With or Without Androgen Deprivation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 960-965.	0.8	38
197	Salvage radiotherapy: A plea for dose-escalation with intensity-modulated radiotherapy. <i>European Journal of Cancer</i> , 2012, 48, 1415-1416.	2.8	6
198	High-Dose Salvage Intensity-Modulated Radiotherapy With or Without Androgen Deprivation After Radical Prostatectomy for Rising or Persisting Prostate-Specific Antigen: 5-Year Results. <i>European Urology</i> , 2011, 60, 842-849.	1.9	74

#	ARTICLE	IF	CITATIONS
199	Delineation of the Postprostatectomy Prostate Bed Using Computed Tomography: Interobserver Variability Following the EORTC Delineation Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e143-e149.	0.8	41
200	Intensity-Modulated Radiotherapy: The Gold Standard for Postprostatectomy Irradiation?. <i>European Urology</i> , 2011, 60, 1149-1150.	1.9	0
201	Analysis of Prostate Bed Motion Using Daily Cone-Beam Computed Tomography During Postprostatectomy Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 188-194.	0.8	61
202	Volumetric Arc Therapy and Intensity-Modulated Radiotherapy for Primary Prostate Radiotherapy With Simultaneous Integrated Boost to Intraprostatic Lesion With 6 and 18 MV: A Planning Comparison Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 920-926.	0.8	90
203	A Matched Control Analysis of Adjuvant and Salvage High-Dose Postoperative Intensity-Modulated Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1316-1322.	0.8	84
204	Adjuvant High-Dose Intensity-Modulated Radiotherapy after Radical Prostatectomy for Prostate Cancer: Clinical Results in 104 Patients. <i>European Urology</i> , 2009, 56, 669-677.	1.9	66
205	Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. <i>Radiotherapy and Oncology</i> , 2008, 89, 205-213.	0.6	78
206	F-18 Fluorodeoxyglucose PET/CT Scanning in the Diagnostic Work-up of a Primary Pericardial Mesothelioma. <i>Journal of Thoracic Imaging</i> , 2008, 23, 35-38.	1.5	25